The team reported the following progress:

**January 2021**
- The team is still actively working on a lung plasma proteomic signature and plans to look at the combination of the two assays.

**February 2020**
- The team published their work with ctDNA in which they developed an assay called Lung Cancer Likelihood in Plasma (Lung-CLiP), showing that it can robustly discriminate early-stage lung cancer patients from risk-matched controls.

**January 2019**
- The team developed a preliminary model of the Lung Cancer Interception Assay (LCIA) for use in conjunction with low dose CT scans which integrates blood-based assays that examine circulating tumor cells, circulating tumor DNA (ctDNA) and plasma proteomics.
- The ctDNA assay using the tumor informed approach demonstrated fairly good sensitivity at a specificity of 90%.

**June 2018**
- The team has enrolled 43 individuals undergoing lung resection for suspected or known early-stage lung cancer and 58 individuals undergoing low-dose CT scans. The goal is to collect blood samples from these individuals for analysis.
- The team has started analyzing blood samples from 20 individuals, attempting to detect circulating DNA and tumor cells in order to predict which patients will develop lung cancer. The researchers are also working to improve these detection methods and increase their sensitivity.

The team added plasma proteomics pilot assays and assessed 34 early-stage lung cancer cases and 33 smoker control subjects. Some of the protein markers found by this method are known to be associated with lung cancer.